Alzheimer's Disease
Conditions
Keywords
Alzheimer's disease
Brief summary
The study is designed to investigate the effects of rilapladib on biomarkers related to the Alzheimer's disease, and cognitive function.
Detailed description
The study is in subjects with Alzheimer's disease and evidence of cerebrovascular disease (CVD) who are currently treated with an acetylcholinesterase inhibitor (AChEI) and/or memantine. The study is a randomized, double-blind, placebo controlled, parallel group, repeat dose design, in which subjects (up to 60 randomized subjects per arm) will receive oral placebo or rilapladib (250 mg), once daily for 24 weeks in addition to their stable background AD therapy consisting of an acetylcholinesterase inhibitor (AChEI) and/or memantine. Subjects will take 250mg of rilapladib or placebo once daily for a period of 24 weeks. The total duration of participation for each subject will be approximately 30 weeks comprising approximately 4 weeks screening, 24 weeks treatment and 2 weeks follow-up. From the time of randomization and throughout the treatment period subjects will attend visits after 1 week, 4 weeks and thereafter every 4 weeks until Week 24. A follow-up visit will occur approximately 2 weeks after the final dose of study medication. Cognitive assessments will be performed at the screening visit, at the randomization (baseline) visit and at weeks 12 and 24 of the treatment period. Cerebrospinal fluid (CSF) samples will be taken via lumbar puncture at baseline and Week 24 for biomarker analyses related to Alzheimer's disease. Blood samples will be collected throughout the study for pharmacokinetics and a range of biomarker analyses. A range of safety and tolerability assessments will also be performed (including vital signs, laboratory tests, eye examinations and ECGs).
Interventions
DRUG250mg rilapladib
Experimental Drug
DRUGplacebo
Placebo comparator
Sponsors
GlaxoSmithKline
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
50 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. A clinical diagnosis of possible Alzheimer's disease in accordance with the National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria, with radiological (Magnetic Resonance Imaging \[MRI\] or Computed Tomography \[CT\]) evidence of significant cerebrovascular disease (CVD), assessed within the last 12 months 2. Male or female between 50 and 80 years of age inclusive, at the time of signing the informed consent. 3. Subject has a documented history of at least 6 months of ongoing Alzheimer's disease therapy (AChEIs and/or memantine) with stable dosing for at least the last 2 months (and with no intent to change for the duration of the study). 4. Mini-Mental Status Examination (MMSE) score between 20 and 26 at Screening. 5. Clinical Dementia Rating Scale (CDR) score of 0.5 or 1.0 at Screening. 6. A female subject is eligible to participate if she is of non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea; or of child-bearing potential and agrees to use acceptable contraception methods 7. Subject has provided full written informed consent prior to the performance of any protocol-specified procedure; or if the subject is unable to provide informed consent due to cognitive status, the subject will provide assent and full written informed consent will be provided by a legally acceptable representative 8. The subject has a dedicated caregiver who is willing to supervise participation in the study 9. In the opinion of the investigator, the subject has the ability to comply with study procedures (cognitive and other testing) and is fluent in the language used for the administration of the cognitive tests.
Exclusion criteria
1. History and/or evidence of any other CNS disorder that could be interpreted as a cause of dementia: e.g. structural or developmental abnormality, epilepsy, infectious, degenerative or inflammatory/demyelinating CNS conditions such as, Parkinson's disease and frontotemporal dementia 2. History of significant psychiatric illness such as schizophrenia or bipolar affective disorder that in the opinion of the Investigator would interfere with participation in the study; major depressive disorder (according to DSM-IV) in the past year; current active depression requiring initiation of treatment (or is believed to account for substantial degree of cognitive impairment) 3. Evidence of the following disorders: current vitamin B12 deficiency, positive syphilis serology (unless neurosyphilis was ruled out) or active thyroid dysfunction (particularly suggestive of hypothyroidism), including abnormally high or low serum levels of thyroid stimulating hormone (TSH), where this is thought to be the cause of, or to contribute to the severity of the subject's dementia. 4. History of alcohol or other substance abuse, according to the DSM-IV criteria, or recent or remote history of the same if that could be a contributing factor to dementia. 5. History of intra cerebral haemorrhage due to any of the following causes: cerebral amyloid angiopathy, uncontrolled hypertension, cerebral arteriovenous malformation, coagulopathy, CNS vasculitis or any other condition that the investigator and/or medical monitor considers as a relevant risk factor for intracerebral haemorrhage 6. Recent (i.e.,\<6 months from Screening Visit) cardiovascular event defined as: 1. ST-elevation MI or non-ST-elevation MI, confirmed by cardiac enzyme elevation and ECG changes 2. coronary revascularization (percutaneous coronary intervention or coronary artery bypass graft ) 3. stroke of any etiology 4. resuscitated sudden death 5. prior carotid surgery or stenting procedure 7. Poorly controlled hypertension despite lifestyle modifications and pharmacotherapy (either systolic blood pressure \>160mmHg or diastolic blood pressure \>110mmHg) 8. QTcB interval \>450 msec; or QTcB \> 480 msec in subjects with bundle branch block based on ECG assessment at the Screening visit. 9. HbA1c \>12.0 at Screening, or uncontrolled diabetes in the opinion of the investigator. 10. History of glaucoma or any other findings in the baseline eye exam that, in the opinion of the investigator, would exclude the subject from participation in the study. 11. History of adult asthma (or reactive airway disease) manifested by bronchospasm in the past 6 months, or currently taking regular anti-asthmatic medication(s). 12. Previous history of anaphylaxis, severe allergic reaction or history of hypersensitivity to any of the components of the formulation. 13. Significant abnormalities on clinical chemistry, haematology or urinalysis at Screening, including clinically significant anaemia. 14. History of chronic viral hepatitis (including presence of B surface antigen or hepatitis C antibody), or other chronic hepatic disorders. 15. Abnormal Screening blood tests exceeding any of the limits defined below: 1. Alanine transaminase (ALT) or aspartate transaminase (AST) \>1.5 x the upper limit of normal (ULN) 2. Alkaline phosphatase (AP) and bilirubin \>1.5X ULN (isolated bilirubin \>1.5x ULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%). 3. Calculated creatinine clearance \< 30 ml/min (per Cockcroft & Gault) at Screening 16. Other clinically significant abnormality on physical (including neurological), laboratory or ECG examination that could be detrimental to the subject in the opinion of the Investigator or could compromise the integrity of the study. 17. Planned major surgery within the study period. 18. Use of systemic steroids or other immunosuppressants within the last 30 days prior to screening. 19. Current treatment with barbiturates, MAO inhibitors, butyrophenones, phenothiazines and other conventional antipsychotic within 30 days or 5 half-lives prior to Screening, whichever is longer. 20. Treatment with antidepressants, (other than MAO inhibitors), thyroid hormones, atypical antipsychotics (e.g. risperidone), benzodiazepines and other sedatives / hypnotics unless prescribed at a stable dose for at least 2 months prior to Screening. Note: Benzodiazepines or other sedatives/hypnotics (including antihistamines) with half-life less than 6 hours can be taken on a prn (as needed) basis but must not be taken within 5 half lives prior to cognitive testing. 21. Current treatment with known potent inhibitors of CYP3A4 (e.g. ketoconazole, rifampin, modafinil). 22. Current treatment with known potent Pgp inhibitors (itraconazole, ketoconazole, cyclosporin, loperamide, diltiazem, verapamil, spironolactone, quinidine, bepridil, quinine, carvedilol) 23. Cognitive tasks prescribed for cognitive rehabilitation and performed under medical supervision in the 6 months prior to screening and/or during study 24. Investigational medications or devices including symptomatic AD treatment during the 60 days prior to the Screening visit, or within 5 half-lives of use of the investigational drug prior to the Screening Visit, whichever is longer. 25. Participation in another investigational drug (with the exception of anti-amyloid monoclonal antibodies \[mAbs\]) or device study where subject was treated chronically (i.e. \> 1 single dose) with a study agent intended to impact AD progression during the 12 months prior to the Screening visit. 1. Subjects who participated in an investigational drug study that involved chronic dosing with a monoclonal antibody at any time in the past are excluded from this study, unless it is known that they received placebo during the previous study. 2. Subjects who participated in previous single-dose studies of anti-amyloid mAbs will be permitted provided the subject's dose of the mAb is at least 5 half-lives removed; the subjects did not experience any moderate adverse events classified as possibly drug-related or any serious adverse event during that study; the subject did not drop out of the previous study (i.e. completed all safety assessments) 26. Subjects, who in the investigator's judgement, pose a significant suicide risk (e.g. history of suicidal behaviour in the last 6 months and/or any suicidal ideation of type 4 or 5 on the C-SSRS in the last 2 months). 27. Subject or caregiver is an immediate family member or employee of the participating Investigator, any of the participating site staff or GSK staff. 28. Any contraindication to lumbar puncture or insertion of CSF catheter, including but not limited to 1. Thrombocytopenia or other coagulation disorders (including subjects receiving coumarin-derived anti-coagulants or low-molecular-weight heparin). 2. The presence of cutaneous or soft tissue infection overlying or adjacent to the site of lumbar puncture. 3. Previous spinal surgery that could complicate access to the subarachnoid space. 4. Suspicion of increased intracranial pressure due to a cerebral mass.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline (Day 0) in Cerebral Spinal Fluid (CSF) Amyloid Beta Peptide (Abeta) 42 and Abeta40 at Week 24 | Baseline (Day 0) and Week 24 | CSF Abeta biomarkers (Abeta42, Abeta40) were assessed at Baseline visit (Day 0) and Week 24 (Day 168). Change from Baseline in CSF Abeta42 and Abeta40 are summarized. Baseline and Week 24 study visits were taken place at approximately the same time of day in the morning (preferably between 08:00 and 12:00) to improve the reliability of CSF. Baseline value was defined as the latest Day 0 value. Change from Baseline was calculated as post-dose (Week 24) visit value minus Baseline value. The data is presented in for adjusted mean and standard error of adjusted mean. |
| Change From Baseline (Day 0) in CSF Abeta42/ Abeta40 Ratio at Week 24 | Baseline (Day 0) and Week 24 | CSF Abeta biomarkers (Abeta42, Abeta40) were assessed at Baseline visit (Day 0) and Week 24 (Day 168). Change from Baseline in CSF Abeta42/Abeta40 ratio is summarized. Baseline and Week 24 study visits were taken place at approximately the same time of day in the morning (preferably between 08:00 and 12:00) to improve the reliability of CSF. Baseline value was defined as the latest Day 0 value. Change from Baseline was calculated as post-dose (Week 24) visit value minus Baseline value. The data is presented in for adjusted mean and standard error of adjusted mean. |
| Change From Baseline (Day 0) in CSF Tau and Phosphorylated Tau (P-tau) Measures at Week 24 | Baseline (Day 0) and Week 24 | CSF tau and P-tau were assessed at Baseline visit (Day 0) and Week 24 (Day 168). Change from Baseline in CSF tau and P-tau was summarized. Baseline and Week 24 study visits were taken place at approximately the same time of day in the morning (preferably between 08:00 and 12:00) to improve the reliability of CSF. Baseline value was defined as the latest Day 0 value. Change from Baseline was calculated as post-dose (Week 24) visit value minus Baseline value. The data is presented in for adjusted mean and standard error of adjusted mean. |
| Change From Baseline (Day 0) in the Computerized Test Battery for Cognition (CogState) Battery Working Memory/Executive Function (WM/EF) Composite Score at Week 24 | Baseline (Day 0) and Week 24 | The WM/EF composite score was comprised of 5 functional tests including 1) Controlled oral word association which measured language fluency, planning and working memory, 2) Category naming: It measures semantic fluency, planning and working memory, 3) One-back: This is a measure of working memory. 4) Trail B: This is a measure of motor speed, visual scanning, and visual-motor integration. This test required attention and cognitive flexibility. 5) Go No-Go task: This test evaluate accuracy and reaction time for each response. The composite score calculated by standardizing the total score: sum of all responses obtained from these 5 functional test by using the formula (Total score of ITT population at baseline - Total score at Week 24) /standard deviation of mean total mean score at baseline. The observed composite score ranged from minimum -1.474 and maximum 1.596. Lower score means better cognitive status. Change from Baseline was calculated as post-dose visit minus Baseline value. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline (Day 0) in CogState Battery Overall Composite Score | Baseline (Day 0) and Week 12 (Day 84), Week 24 (Day 168) | CogState battery overall composite score comprised of 8 functional tests 1) Controlled oral word association test measured language fluency, planning and working memory. 2) Category naming test measured semantic fluency, planning and working memory. 3) One-back test measured working memory. 4) Trail B test measured motor speed, visual scanning and visual-motor integration, required attention and cognitive flexibility. 5) Go No-Go task evaluated accuracy and reaction time for each response. 6) International shopping list immediate and delayed recall tests measured episodic memory. 7) Identification task test assessed visual attention. 8) Trail A test measured psychomotor speed and attention. Composite score= total score (sum of all responses from 8 functional test) by formula (Total score at baseline - Week 24) / SD of total score at baseline. Score ranged: -1.070 to 0.907. Lower score indicated the better cognitive status. Change from Baseline= post-dose visit minus Baseline value |
| Change From Baseline (Day 0) in CSF Albumin Quotients at Week 24 | Baseline (Day 0) and Week 24 | CSF albumin quotient was assessed at Baseline visit (Day 0) and Week 24 (Day 168). Change from Baseline in albumin quotient is summarized. Baseline and Week 24 study visits were taken place at approximately the same time of day in the morning (preferably between 08:00 and 12:00) to improve the reliability of CSF. Baseline value was defined as the latest Day 0 value. Change from Baseline was calculated as post-dose (Week 24) visit value minus Baseline value. The data is presented in for adjusted mean and standard error of adjusted mean. |
| Change From Baseline (Day 0) in CogState Battery Attention Composite Score | Baseline (Day 0) and Week 12 (Day 84), Week 24 (Day 168) | CogState battery attention composite score comprised of 2 functional tests including 1) Identification task test assessed visual attention and 2) Trail A test measured psychomotor speed and attention. Composite score calculated by standardizing the total score (sum of all responses from 2 functional test) by formula (Total score at baseline - Week 24) / SD of total score at baseline. The observed composite score ranged from minimum -1.756 and maximum 1.330. Higher score indicated the better attention. Baseline value was defined as the latest Day 0 value and Change from Baseline was calculated as post-dose visit minus Baseline value |
| Change From Baseline (Day 0) in Plasma Levels of Abeta42 and Abeta40 at Week 24 | Baseline (Day 0) and Week 24 | Plasma Abeta biomarkers (Abeta42, Abeta40) were assessed at Baseline visit (Day 0) and Week 24 (Day 168). Change from Baseline in plasma Abeta42 and Abeta40 are summarized. Baseline value was defined as the latest Day 0 value. Change from Baseline was calculated as post-dose (Week 24) visit value minus Baseline value. The data is presented in for adjusted mean and standard error of adjusted mean. |
| Change From Baseline (Day 0) in Plasma Levels of Abeta42/Abeta40 Ratio at Week 24 | Baseline (Day 0) and Week 24 | Plasma Abeta biomarkers (Abeta42, Abeta40) were assessed at Baseline visit (Day 0) and Week 24 (Day 168). Change from Baseline in plasma Abeta42/Abeta40 ratio is summarized. Baseline value was defined as the latest Day 0 value. Change from Baseline was calculated as post-dose (Week 24) visit value minus Baseline value. The data is presented in for adjusted mean and standard error of adjusted mean. |
| Percentage Inhibition in Plasma Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Activity at Week 24 | Baseline (Day 0) and Week 24 | Plasma Lp-PLA2 was assessed at Baseline visit (Day 0) and Week 24 (Day 168). Percentage inhibition in plasma Lp-PLA2 activity ratio is summarized. Percentage inhibition was calculated by dividing change from Baseline in plasma LpPLA2 by Baseline LpPLA2 multiplied by -100. Baseline value was defined as the latest Day 0 value. Change from Baseline was calculated as post-dose (Week 24) visit value minus Baseline value. |
Countries
Bulgaria, Canada, Germany, Italy, Norway, Spain, Sweden
Participant flow
Recruitment details
Participants with Alzheimer's disease (AD) were randomized to either rilapladib or placebo from October-2011 to February-2013. The study duration was approximately 30 weeks (screening: 4 weeks, treatment: 24 weeks and follow-up: 2 weeks).
Pre-assignment details
Total of 170 participants were screened, of which 124 were randomized in 24 centres. Out of 124 participants, one was excluded from safety population due to randomization error. Out of 123 participants, 2 were excluded due to unavailability of post-baseline efficacy data. Intention to treat (ITT) population consisted of 121 participants.
Participants by arm
| Arm | Count |
|---|---|
| Placebo Once Daily Participants randomized to receive oral placebo tablet once daily following breakfast for a period of 24 weeks. In addition to their stable background therapy consisting of an AChEI and/or memantine. | 61 |
| Rilapladib 250 mg Once Daily Participants randomized to receive oral rilapladib 250 mg tablet once daily following breakfast for a period of 24 weeks. In addition to their stable background therapy consisting of an AChEI and/or memantine. | 60 |
| Total | 121 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Adverse Event | 2 | 7 |
| Overall Study | Lost to Follow-up | 0 | 1 |
| Overall Study | Protocol Violation | 1 | 0 |
| Overall Study | Withdrawal by Subject | 3 | 1 |
Baseline characteristics
| Characteristic | Placebo Once Daily | Rilapladib 250 mg Once Daily | Total |
|---|---|---|---|
| Age, Continuous | 73.1 Years STANDARD_DEVIATION 5.4 | 72.9 Years STANDARD_DEVIATION 5.15 | 73.0 Years STANDARD_DEVIATION 5.26 |
| Race/Ethnicity, Customized White - White/Caucasian/European Heritage | 61 Participants | 60 Participants | 121 Participants |
| Sex: Female, Male Female | 28 Participants | 32 Participants | 60 Participants |
| Sex: Female, Male Male | 33 Participants | 28 Participants | 61 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 1 / 62 | 1 / 61 |
| other Total, other adverse events | 23 / 62 | 16 / 61 |
| serious Total, serious adverse events | 5 / 62 | 8 / 61 |
Outcome results
Primary
Change From Baseline (Day 0) in Cerebral Spinal Fluid (CSF) Amyloid Beta Peptide (Abeta) 42 and Abeta40 at Week 24
CSF Abeta biomarkers (Abeta42, Abeta40) were assessed at Baseline visit (Day 0) and Week 24 (Day 168). Change from Baseline in CSF Abeta42 and Abeta40 are summarized. Baseline and Week 24 study visits were taken place at approximately the same time of day in the morning (preferably between 08:00 and 12:00) to improve the reliability of CSF. Baseline value was defined as the latest Day 0 value. Change from Baseline was calculated as post-dose (Week 24) visit value minus Baseline value. The data is presented in for adjusted mean and standard error of adjusted mean.
Time frame: Baseline (Day 0) and Week 24
Population: ITT population. Only those participants available at the specified time points were analyzed.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo Once Daily | Change From Baseline (Day 0) in Cerebral Spinal Fluid (CSF) Amyloid Beta Peptide (Abeta) 42 and Abeta40 at Week 24 | Abeta42 | -6.3 Nanograms per Liter | Standard Error 18.1 |
| Placebo Once Daily | Change From Baseline (Day 0) in Cerebral Spinal Fluid (CSF) Amyloid Beta Peptide (Abeta) 42 and Abeta40 at Week 24 | Abeta40 | -77.4 Nanograms per Liter | Standard Error 181.33 |
| Rilapladib 250 mg Once Daily | Change From Baseline (Day 0) in Cerebral Spinal Fluid (CSF) Amyloid Beta Peptide (Abeta) 42 and Abeta40 at Week 24 | Abeta42 | 33.6 Nanograms per Liter | Standard Error 19.02 |
| Rilapladib 250 mg Once Daily | Change From Baseline (Day 0) in Cerebral Spinal Fluid (CSF) Amyloid Beta Peptide (Abeta) 42 and Abeta40 at Week 24 | Abeta40 | -327.7 Nanograms per Liter | Standard Error 190.56 |
p-value: 0.13395% CI: [-12.4, 92]ANCOVA
p-value: 0.82995% CI: [-771.9, 271.2]ANCOVA
Primary
Change From Baseline (Day 0) in CSF Abeta42/ Abeta40 Ratio at Week 24
CSF Abeta biomarkers (Abeta42, Abeta40) were assessed at Baseline visit (Day 0) and Week 24 (Day 168). Change from Baseline in CSF Abeta42/Abeta40 ratio is summarized. Baseline and Week 24 study visits were taken place at approximately the same time of day in the morning (preferably between 08:00 and 12:00) to improve the reliability of CSF. Baseline value was defined as the latest Day 0 value. Change from Baseline was calculated as post-dose (Week 24) visit value minus Baseline value. The data is presented in for adjusted mean and standard error of adjusted mean.
Time frame: Baseline (Day 0) and Week 24
Population: ITT Population. Only those participants with data available at the indicated time points were analyzed.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo Once Daily | Change From Baseline (Day 0) in CSF Abeta42/ Abeta40 Ratio at Week 24 | 0.002 Ratio | Standard Error 0.0068 |
| Rilapladib 250 mg Once Daily | Change From Baseline (Day 0) in CSF Abeta42/ Abeta40 Ratio at Week 24 | 0.018 Ratio | Standard Error 0.0071 |
95% CI: [-0.003, 0.036]
Primary
Change From Baseline (Day 0) in CSF Tau and Phosphorylated Tau (P-tau) Measures at Week 24
CSF tau and P-tau were assessed at Baseline visit (Day 0) and Week 24 (Day 168). Change from Baseline in CSF tau and P-tau was summarized. Baseline and Week 24 study visits were taken place at approximately the same time of day in the morning (preferably between 08:00 and 12:00) to improve the reliability of CSF. Baseline value was defined as the latest Day 0 value. Change from Baseline was calculated as post-dose (Week 24) visit value minus Baseline value. The data is presented in for adjusted mean and standard error of adjusted mean.
Time frame: Baseline (Day 0) and Week 24
Population: ITT Population. Only those participants available at the specified time points were analyzed.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo Once Daily | Change From Baseline (Day 0) in CSF Tau and Phosphorylated Tau (P-tau) Measures at Week 24 | P-tau | 1.3 Nanograms per Liter | Standard Error 1.67 |
| Placebo Once Daily | Change From Baseline (Day 0) in CSF Tau and Phosphorylated Tau (P-tau) Measures at Week 24 | CSF tau | 38.2 Nanograms per Liter | Standard Error 29.98 |
| Rilapladib 250 mg Once Daily | Change From Baseline (Day 0) in CSF Tau and Phosphorylated Tau (P-tau) Measures at Week 24 | P-tau | -1.7 Nanograms per Liter | Standard Error 1.76 |
| Rilapladib 250 mg Once Daily | Change From Baseline (Day 0) in CSF Tau and Phosphorylated Tau (P-tau) Measures at Week 24 | CSF tau | -18.8 Nanograms per Liter | Standard Error 31.9 |
p-value: 0.90295% CI: [-144.5, 30.3]ANCOVA
p-value: 0.89295% CI: [-7.9, 1.8]ANCOVA
Primary
Change From Baseline (Day 0) in the Computerized Test Battery for Cognition (CogState) Battery Working Memory/Executive Function (WM/EF) Composite Score at Week 24
The WM/EF composite score was comprised of 5 functional tests including 1) Controlled oral word association which measured language fluency, planning and working memory, 2) Category naming: It measures semantic fluency, planning and working memory, 3) One-back: This is a measure of working memory. 4) Trail B: This is a measure of motor speed, visual scanning, and visual-motor integration. This test required attention and cognitive flexibility. 5) Go No-Go task: This test evaluate accuracy and reaction time for each response. The composite score calculated by standardizing the total score: sum of all responses obtained from these 5 functional test by using the formula (Total score of ITT population at baseline - Total score at Week 24) /standard deviation of mean total mean score at baseline. The observed composite score ranged from minimum -1.474 and maximum 1.596. Lower score means better cognitive status. Change from Baseline was calculated as post-dose visit minus Baseline value.
Time frame: Baseline (Day 0) and Week 24
Population: ITT Population. Only those participants with data available at the indicated time points were analyzed. The data is presented in for adjusted mean and standard error of adjusted mean.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo Once Daily | Change From Baseline (Day 0) in the Computerized Test Battery for Cognition (CogState) Battery Working Memory/Executive Function (WM/EF) Composite Score at Week 24 | -0.150 Scores on a scale | Standard Error 0.0501 |
| Rilapladib 250 mg Once Daily | Change From Baseline (Day 0) in the Computerized Test Battery for Cognition (CogState) Battery Working Memory/Executive Function (WM/EF) Composite Score at Week 24 | 0.016 Scores on a scale | Standard Error 0.0538 |
p-value: 0.02695% CI: [0.021, 0.313]Mixed-Model Repeated Measures analysis
Secondary
Change From Baseline (Day 0) in CogState Battery Attention Composite Score
CogState battery attention composite score comprised of 2 functional tests including 1) Identification task test assessed visual attention and 2) Trail A test measured psychomotor speed and attention. Composite score calculated by standardizing the total score (sum of all responses from 2 functional test) by formula (Total score at baseline - Week 24) / SD of total score at baseline. The observed composite score ranged from minimum -1.756 and maximum 1.330. Higher score indicated the better attention. Baseline value was defined as the latest Day 0 value and Change from Baseline was calculated as post-dose visit minus Baseline value
Time frame: Baseline (Day 0) and Week 12 (Day 84), Week 24 (Day 168)
Population: ITT Population. Only those participants available at the specified time points were analyzed.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo Once Daily | Change From Baseline (Day 0) in CogState Battery Attention Composite Score | Week 12 | -0.062 Scores on a scale | Standard Error 0.0684 |
| Placebo Once Daily | Change From Baseline (Day 0) in CogState Battery Attention Composite Score | Week 24 | -0.089 Scores on a scale | Standard Error 0.0686 |
| Rilapladib 250 mg Once Daily | Change From Baseline (Day 0) in CogState Battery Attention Composite Score | Week 12 | -0.125 Scores on a scale | Standard Error 0.0693 |
| Rilapladib 250 mg Once Daily | Change From Baseline (Day 0) in CogState Battery Attention Composite Score | Week 24 | -0.019 Scores on a scale | Standard Error 0.0729 |
95% CI: [-0.257, 0.13]Mixed-Model Repeated Measures analysis
95% CI: [-0.13, 0.269]Mixed-Model Repeated Measures analysis
Secondary
Change From Baseline (Day 0) in CogState Battery Overall Composite Score
CogState battery overall composite score comprised of 8 functional tests 1) Controlled oral word association test measured language fluency, planning and working memory. 2) Category naming test measured semantic fluency, planning and working memory. 3) One-back test measured working memory. 4) Trail B test measured motor speed, visual scanning and visual-motor integration, required attention and cognitive flexibility. 5) Go No-Go task evaluated accuracy and reaction time for each response. 6) International shopping list immediate and delayed recall tests measured episodic memory. 7) Identification task test assessed visual attention. 8) Trail A test measured psychomotor speed and attention. Composite score= total score (sum of all responses from 8 functional test) by formula (Total score at baseline - Week 24) / SD of total score at baseline. Score ranged: -1.070 to 0.907. Lower score indicated the better cognitive status. Change from Baseline= post-dose visit minus Baseline value
Time frame: Baseline (Day 0) and Week 12 (Day 84), Week 24 (Day 168)
Population: ITT Population. Only those participants available at the specified time points were analyzed. The data is presented in for adjusted mean and standard error of adjusted mean.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo Once Daily | Change From Baseline (Day 0) in CogState Battery Overall Composite Score | Week 12 | 0.013 Scores on a scale | Standard Error 0.0438 |
| Placebo Once Daily | Change From Baseline (Day 0) in CogState Battery Overall Composite Score | Week 24 | -0.121 Scores on a scale | Standard Error 0.0445 |
| Rilapladib 250 mg Once Daily | Change From Baseline (Day 0) in CogState Battery Overall Composite Score | Week 12 | -0.054 Scores on a scale | Standard Error 0.0444 |
| Rilapladib 250 mg Once Daily | Change From Baseline (Day 0) in CogState Battery Overall Composite Score | Week 24 | 0.017 Scores on a scale | Standard Error 0.0466 |
95% CI: [-0.191, 0.057]Mixed-Model Repeated Measures analysis
p-value: 0.98295% CI: [0.01, 0.267]Mixed-Model Repeated Measures analysis
Secondary
Change From Baseline (Day 0) in CSF Albumin Quotients at Week 24
CSF albumin quotient was assessed at Baseline visit (Day 0) and Week 24 (Day 168). Change from Baseline in albumin quotient is summarized. Baseline and Week 24 study visits were taken place at approximately the same time of day in the morning (preferably between 08:00 and 12:00) to improve the reliability of CSF. Baseline value was defined as the latest Day 0 value. Change from Baseline was calculated as post-dose (Week 24) visit value minus Baseline value. The data is presented in for adjusted mean and standard error of adjusted mean.
Time frame: Baseline (Day 0) and Week 24
Population: ITT Population. Only those participants with data available at the indicated time points were analyzed.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo Once Daily | Change From Baseline (Day 0) in CSF Albumin Quotients at Week 24 | 0.11 Nanograms per Liter | Standard Error 0.172 |
| Rilapladib 250 mg Once Daily | Change From Baseline (Day 0) in CSF Albumin Quotients at Week 24 | -0.13 Nanograms per Liter | Standard Error 0.184 |
p-value: 0.82895% CI: [-0.74, 0.26]ANCOVA
Secondary
Change From Baseline (Day 0) in Plasma Levels of Abeta42/Abeta40 Ratio at Week 24
Plasma Abeta biomarkers (Abeta42, Abeta40) were assessed at Baseline visit (Day 0) and Week 24 (Day 168). Change from Baseline in plasma Abeta42/Abeta40 ratio is summarized. Baseline value was defined as the latest Day 0 value. Change from Baseline was calculated as post-dose (Week 24) visit value minus Baseline value. The data is presented in for adjusted mean and standard error of adjusted mean.
Time frame: Baseline (Day 0) and Week 24
Population: ITT Population. Only those participants with data available at the indicated time points were analyzed.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo Once Daily | Change From Baseline (Day 0) in Plasma Levels of Abeta42/Abeta40 Ratio at Week 24 | -0.010 Ratio | Standard Error 0.0045 |
| Rilapladib 250 mg Once Daily | Change From Baseline (Day 0) in Plasma Levels of Abeta42/Abeta40 Ratio at Week 24 | -0.012 Ratio | Standard Error 0.0047 |
95% CI: [-0.016, 0.01]Mixed-Model Repeated Measures analysis
Secondary
Change From Baseline (Day 0) in Plasma Levels of Abeta42 and Abeta40 at Week 24
Plasma Abeta biomarkers (Abeta42, Abeta40) were assessed at Baseline visit (Day 0) and Week 24 (Day 168). Change from Baseline in plasma Abeta42 and Abeta40 are summarized. Baseline value was defined as the latest Day 0 value. Change from Baseline was calculated as post-dose (Week 24) visit value minus Baseline value. The data is presented in for adjusted mean and standard error of adjusted mean.
Time frame: Baseline (Day 0) and Week 24
Population: ITT Population. Only those participants available at the specified time points were analyzed.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo Once Daily | Change From Baseline (Day 0) in Plasma Levels of Abeta42 and Abeta40 at Week 24 | Abeta42 | 1.5 Nanograms per Liter | Standard Error 0.9 |
| Placebo Once Daily | Change From Baseline (Day 0) in Plasma Levels of Abeta42 and Abeta40 at Week 24 | Abeta40 | 8.8 Nanograms per Liter | Standard Error 3.91 |
| Rilapladib 250 mg Once Daily | Change From Baseline (Day 0) in Plasma Levels of Abeta42 and Abeta40 at Week 24 | Abeta42 | 0.2 Nanograms per Liter | Standard Error 0.94 |
| Rilapladib 250 mg Once Daily | Change From Baseline (Day 0) in Plasma Levels of Abeta42 and Abeta40 at Week 24 | Abeta40 | 9.7 Nanograms per Liter | Standard Error 4.06 |
95% CI: [-3.9, 1.2]Mixed-Model Repeated Measures analysis
95% CI: [-10.2, 12.2]Mixed-Model Repeated Measures analysis
Secondary
Percentage Inhibition in Plasma Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Activity at Week 24
Plasma Lp-PLA2 was assessed at Baseline visit (Day 0) and Week 24 (Day 168). Percentage inhibition in plasma Lp-PLA2 activity ratio is summarized. Percentage inhibition was calculated by dividing change from Baseline in plasma LpPLA2 by Baseline LpPLA2 multiplied by -100. Baseline value was defined as the latest Day 0 value. Change from Baseline was calculated as post-dose (Week 24) visit value minus Baseline value.
Time frame: Baseline (Day 0) and Week 24
Population: ITT Population. Only those participants with data available at the indicated time points were analyzed.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo Once Daily | Percentage Inhibition in Plasma Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Activity at Week 24 | -3.86 Percent change | Standard Deviation 30.228 |
| Rilapladib 250 mg Once Daily | Percentage Inhibition in Plasma Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Activity at Week 24 | 83.59 Percent change | Standard Deviation 10.483 |